New study to see if emicizumab protects Kids' joints from hemophilia damage

NCT ID NCT07190118

Not yet recruiting Disease control Sponsor: Hasan Kalyoncu University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 20 children with hemophilia A who are starting emicizumab treatment. Researchers will measure pain, joint health, balance, and mobility over time to see if the drug helps protect the musculoskeletal system. The goal is to understand whether emicizumab can reduce long-term joint problems in these children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emicizumab
What this could lead to: If successful, this could show that emicizumab helps protect joints and muscles in children with hemophilia A, potentially improving their long-term physical health.
What could go wrong: This is a small, early-stage study with only 20 participants and no control group. Results may not apply to all children with hemophilia A, and the treatment's long-term effects on joints are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A Musculoskeletal Abnormalities

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A MUSCULOSKELETAL ABNORMALITIES MUSCULOSKELETAL ASSESSMENT

Contacts and locations

Locations

Hasan Kalyoncu University

Gaziantep, Gaziantep, (505) 090-5846, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.